Pharmaceutical giant Novo Nordisk said it is slashing the price of weight-loss and diabetes drugs Ozempic, Wegovy and Rybelsus by more than a third.

Pharmaceutical giant Novo Nordisk said it is slashing the price of weight-loss and diabetes drugs Ozempic, Wegovy and Rybelsus by more than a third.

Novo Nordisk will cut prices of the diabetes and weight loss drugs Ozempic, Rybelsus and Wegovy to $675 effective Jan. 1, 2027.

The cuts aim to make the drugs more accessible to insured patients, particularly people with high-deductible health plans or co-insurance benefit designs.